Clinical Trials Logo

Refractory clinical trials

View clinical trials related to Refractory.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03179930 Active, not recruiting - Lymphoma Clinical Trials

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Start date: June 7, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.

NCT ID: NCT03085173 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Start date: March 15, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this phase I study is to test the safety of different dose levels of specially prepared cells collected from the patient called "modified T cells". The investigators want to find a safe dose of modified T cells for patients with this type of cancer that has progressed after standard therapy. The investigators also want to find out what effects these modified T cells have on the patient and the cancer. For patients who were treated, had progression of disease and were removed from study, duplicate enrollment is permitted if it is determined the patients could receive a benefit. If the patients meet all eligibility criteria, they can be enrolled onto study a second time as a new accrual, and receive treatment in a higher dose level cohort.

NCT ID: NCT02280993 Active, not recruiting - Hodgkin Lymphoma Clinical Trials

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Start date: May 2014
Phase: Phase 1
Study type: Interventional

To combine Brentuximab Vedotin with Dexamethasone, AraC and Cisplatin (DHAP) chemotherapy in patients with Hodgkin lymphoma (HL) refractory to first line chemotherapy or in first relapse is expected to induce a significantly higher (metabolic) complete remission (CR) rate prior to consolidation with BEAM, as judged by FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose)-PET negativity. This will be compared with published data on DHAP salvage only. Increasing the metabolic CR rate prior to consolidation with high dose chemotherapy and autologous stem cell transplantation (ASCT) is expected to improve progression free survival (PFS) and overall survival (OS).